{
    "clinical_study": {
        "@rank": "26580", 
        "acronym": "TIAA", 
        "arm_group": [
            {
                "arm_group_label": "Preemptive group", 
                "arm_group_type": "Active Comparator", 
                "description": "The preemptive group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered within 60 minutes prior to incision.  Each infusion will be administered over 15 minutes as recommended for OfirmevTM administration."
            }, 
            {
                "arm_group_label": "Closure group", 
                "arm_group_type": "Active Comparator", 
                "description": "The closure group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered upon onset of skin closure."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to examine the effects of timing of administration of\n      intravenous (IV) acetaminophen and how timing relates to analgesic efficacy as measured by\n      postoperative pain scores. A maximum of 138 patients meeting inclusion criteria who present\n      for a scheduled total hip replacement under general anesthesia will be randomized into one\n      of two arms: 1) the pre-closure group will receive the first dose administered upon onset of\n      skin closure,  2) the preemptive group will receive the first dose administered within 60\n      minutes prior to incision.  Both groups will receive subsequent doses every 6 hours x 24\n      hours."
        }, 
        "brief_title": "Time of Intravenous Acetaminophen Administration", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Osteoarthritis", 
        "condition_browse": {
            "mesh_term": "Osteoarthritis"
        }, 
        "detailed_description": {
            "textblock": "The purpose of the study is to examine the effects of timing of administration of\n      intravenous (IV) acetaminophen and how timing relates to analgesic efficacy as measured by\n      postoperative pain scores. A maximum of 138 patients meeting inclusion criteria who present\n      for a scheduled total hip replacement under general anesthesia will be randomized into one\n      of two arms: 1) the closure group will receive the first dose of one gram of intravenous\n      acetaminophen administered upon onset of skin closure,  2) the preemptive group will receive\n      the first dose of one gram of intravenous acetaminophen administered within 60 minutes prior\n      to incision.  Both groups will receive subsequent doses of one gram of intravenous\n      acetaminophen every 6 hours x 24 hours. The maximum dose in a 24 hour period will not exceed\n      4 grams according to FDA recommendations."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients 30-75 years of age weighing \u226555 kg scheduled for elective total hip\n             arthroplasty performed under general anesthesia will be included.  As determined by\n             the anesthesia team assigned to the case, eligible patients will also be assigned ASA\n             physical status of I, II, or III and deemed capable of reporting their perceived pain\n             using numeric pain scales and capable of operating a patient controlled anesthesia\n             (PCA) device.\n\n        Exclusion Criteria:\n\n          -  Exclusion criteria include known allergy, hypersensitivity, or contraindication to\n             acetaminophen, history of alcohol or drug abuse, prisoners, emergency THAs, patients\n             with chronic malnutrition or a body mass index (BMI) < 18 kg/m2 and non-English\n             speaking patients. Additional exclusion criteria include impaired liver function\n             defined as AST and ALT each \u2265 twice normal limits and renal dysfunction (creatinine\n             >2.0 mg/dl)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01699815", 
            "org_study_id": "Pro00036568"
        }, 
        "intervention": {
            "arm_group_label": [
                "Preemptive group", 
                "Closure group"
            ], 
            "intervention_name": "Acetaminophen", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Acetaminophen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "acetaminophen", 
            "timing", 
            "arthroplasty"
        ], 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27704"
                }, 
                "name": "Durham Regional Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Time of Intravenous Acetaminophen Administration for Total Hip Arthroplasty", 
        "other_outcome": {
            "measure": "A final outcome measure is to compare patient length of stay (LOS) between groups as measured by day of discharge minus day of admission.", 
            "safety_issue": "No", 
            "time_frame": "Outcome measures will be assessed preoperatively, at 6,12, 18, and 24 hours following the initial administration of the study drug, and at the time of discharge."
        }, 
        "overall_official": {
            "affiliation": "Duke University Health System", 
            "last_name": "Virginia C Muckler, DNP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The primary aim of the study is to compare analgesic efficacy as measured by changes in postoperative pain scores assessed preoperatively, at 6, 12, 18, and 24 hours following the initial administration of the study drug.", 
            "safety_issue": "No", 
            "time_frame": "Outcome measures will be assessed preoperatively, at 6,12, 18, and 24 hours following the initial administration of the study drug, and at the time of discharge."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01699815"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "A secondary aim is to compare changes in postoperative pain medication consumption rates as measured by changes in postoperative pain scores assessed preoperatively, at 6, 12, 18, and 24 hours following the initial administration of the study drug.", 
            "safety_issue": "No", 
            "time_frame": "Outcome measures will be assessed preoperatively, at 6,12, 18, and 24 hours following the initial administration of the study drug, and at the time of discharge."
        }, 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}